Evidence map›Paper›PMID 41469503›Full record

ArticleCommunications biology2025

Label-free human skin imaging with enhanced molecular contrast via time-resolved fluorescence and advanced phasor analysis.

Suman Ranjit, Belen Torrado, Alexander Vallmitjana, Amanda Fedyk Durkin, Alexander Dvornikov, Anand Ganesan, Kristen M Kelly, Mihaela Balu

Erratum issuedAbstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Suman Ranjit *Beckman Laser Institute and Medical Clinic, University of California Irvine, Irvine, CA, USA. suman.ranjit@georgetown.edu.ORCID http://orcid.org/0000-0003-3058-6332
Belen Torrado *Beckman Laser Institute and Medical Clinic, University of California Irvine, Irvine, CA, USA.
Alexander VallmitjanaBeckman Laser Institute and Medical Clinic, University of California Irvine, Irvine, CA, USA.
Amanda Fedyk DurkinBeckman Laser Institute and Medical Clinic, University of California Irvine, Irvine, CA, USA.
Alexander DvornikovBeckman Laser Institute and Medical Clinic, University of California Irvine, Irvine, CA, USA.
Anand GanesanBeckman Laser Institute and Medical Clinic, University of California Irvine, Irvine, CA, USA.
Kristen M KellyBeckman Laser Institute and Medical Clinic, University of California Irvine, Irvine, CA, USA.
Mihaela BaluBeckman Laser Institute and Medical Clinic, University of California Irvine, Irvine, CA, USA. mbalu@uci.edu.ORCID http://orcid.org/0000-0002-8018-5134

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
UCI P30 Skin Center Systems Biology CoreP30AR075047 · NIAMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI ANDERSEN, BOGI, GANESAN, ANAND K · 2019 to 2025
$5.1M
Development of a fast scanning, extended field-of-view multiphoton microscope for clinical skin imagingR01EB026705 · NIBIB · UNIVERSITY OF CALIFORNIA-IRVINE · PI Mihaela Balu, Anand K Ganesan · 2018 to 2026
$4.2M
Fast, large area, multiphoton exoscope (FLAME) for improving early detection of melanomaR01CA259019 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BALU, MIHAELA, KELLY, KRISTEN M · 2022 to 2025
$3.1M
Novel functions of ESRRB in glioblastomaR01CA279195 · NCI · GEORGETOWN UNIVERSITY · PI Rebecca B Riggins · 2024 to 2026
$1.6M
Developing multiparametric fluorescence microscopy to connect metabolism with cellular manipulationsR35GM154815 · NIGMS · GEORGETOWN UNIVERSITY · PI Suman Ranjit · 2024 to 2026
$1.2M
In vivo label free optical imaging of immune cells in human skinR21AR082648 · NIAMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI BALU, MIHAELA, GANESAN, ANAND K · 2023 to 2024
$374k
NCI NIH HHS P30 CA062203NCI NIH HHS R01 CA259019NCI NIH HHS R01 CA279195NIAMS NIH HHS P30 AR075047NIAMS NIH HHS R21 AR082648NIBIB NIH HHS R01 EB026705NIGMS NIH HHS R35 GM154815U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P30CA062203U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA259019U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) P30AR075047U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R21AR082648U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB) R01EB026705U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) 1R35GM154815
6 · The paper itself

Abstract

Current state-of-the-art clinical skin imaging using label-free multiphoton microscopy (MPM) faces challenges due to limited molecular specificity, which hampers the accurate characterization of skin tissues because of overlapping fluorescence signals from multiple molecular components. In this study, we present a novel approach to enhance molecular contrast in MPM clinical skin imaging by leveraging advanced strategies to effectively unmix the various endogenous fluorophores present in the skin with the performance capabilities of a recently developed imaging platform for in vivo time-resolved fluorescence imaging of human skin. By identifying phasor positions of key endogenous skin fluorophores - such as keratin, melanin, free NADH, and protein-bound NADH - we effectively perform multicomponent unmixing in different skin types and conditions, including those with varying levels of pigmentation and metabolic states. The phasor analysis allows for the mapping and quantification of individual fluorescence species and provides comprehensive insight into the dynamic changes in molecular components associated with distinct clinical conditions. This study highlights the effective use of advanced imaging and phasor analysis to improve label-free molecular contrast in clinical skin imaging, leading to advancements in future research focused on precise and timely assessments of skin conditions and monitoring of therapeutic effects.

Indexed as

Microscopy, Fluorescence, MultiphotonMolecular ImagingOptical ImagingSkinFluorescenceHumans

Identifiers

PMID41469503
PMCPMC12868790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.